Letter by Khan and Boyle Regarding Article, “Early Use of N-Acetylcysteine (NAC) With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We congratulate our colleagues in Adelaide for publishing the results of the NACIAM trial (N-Acetylcysteine in Acute Myocardial Infarction).1 In this multicenter randomized controlled trail of 112 patients with ST-segment–elevation myocardial infarction, total ischemic time 30 minutes to 12 hours, Pasupathy et al1 found that the administration of an intravenous infusion of N-acetylcysteine for 48 hours, initiated before primary percutaneous coronary intervention, plus a low-dose nitroglycerin infusion reduced acute myocardial …